DBV Technologies (DBVT) EBITDA (2020 - 2026)
DBV Technologies (DBVT) posted quarterly EBITDA of -$50.6 million for Q2 2026, down 23.11% year-on-year from -$65.8 million in Q2 2025, and down 5.64% on a QoQ basis from -$47.9 million in Q1 2026.
DBV Technologies (DBVT) EBITDA (2020 - 2026) Analysis & Trends
DBV Technologies (DBVT) has reported EBITDA for 7 consecutive years, with -$50.6 million the latest figure, recorded in Q2 2026.
- Quarterly EBITDA fell 23.11% year-over-year to -$50.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$177.8 million (down 45.89% YoY) and the FY2025 annual result came in at -$147.1 million, down 26.13% from the prior year.
- EBITDA fell to -$50.6 million in Q2 2026 per DBVT's latest filing, from -$47.9 million in the prior quarter.
- Over the last five years, EBITDA for DBVT reached as high as -$11.9 million in Q4 2023 and fell as low as -$50.6 million in Q2 2026.
- A 5-year average of -$29.7 million and a median of -$27.6 million in 2024 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2022 — EBITDA slumped 182.09% — and 2023, when it surged 68.65%.
- Year by year, EBITDA stood at -$38.0 million in 2022, then surged by 68.65% to -$11.9 million in 2023, then sank by 100.18% to -$23.9 million in 2024, then tumbled by 88.81% to -$45.1 million in 2025, then decreased by 12.32% to -$50.6 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$50.6 million, -$47.9 million, and -$45.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | DBV Technologies | 267.50 Mn | 92.60 Mn | - | -50.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -50.60 Mn |
| Mar 31, 2026 | -47.90 Mn |
| Dec 31, 2025 | -45.05 Mn |
| Sep 30, 2025 | -34.28 Mn |
| Jun 30, 2025 | -41.10 Mn |
| Mar 31, 2025 | -26.60 Mn |
| Dec 31, 2024 | -23.86 Mn |
| Sep 30, 2024 | -30.33 Mn |
| Jun 30, 2024 | -33.84 Mn |
| Mar 31, 2024 | -28.56 Mn |
| Dec 31, 2023 | -11.92 Mn |
| Sep 30, 2023 | -18.27 Mn |
| Jun 30, 2023 | -25.08 Mn |
| Mar 31, 2023 | -21.17 Mn |
| Dec 31, 2022 | -38.02 Mn |
| Sep 30, 2022 | -18.02 Mn |
| Jun 30, 2022 | -23.82 Mn |
| Mar 31, 2022 | -16.77 Mn |
| Dec 31, 2021 | -13.48 Mn |
| Sep 30, 2021 | -24.37 Mn |